Post-treatment survivorship remains defined by ongoing monitoring, potential long-term maintenance medications, and an enduring inability to fully “move on” from recurrence risk. Nonspecific symptoms ...
Tevimbra combined with chemotherapy showed significant survival benefits in esophageal cancer, reducing the risk of death by 34% in a phase 3 trial. Keytruda, combined with Herceptin and chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results